An analysis digs into whether the FDA really is approving drugs faster under Commissioner Scott Gottlieb, MD; a clinical trial for a Parkinson's disease drug halts enrollment after 5 deaths; and California fines Anthem $5 million for poor response to consumer complaints.
The FDA has been trumpeting the faster rate of drug approvals under Commissioner Scott Gottlieb, MD, but the process may not be any faster than before. An analysis by STAT of the difference between the approval date of drugs and the PDUFA date has found that the FDA is right in line with previous years. On average, drugs in 2017 are getting approved 30 days ahead of schedule, but the analysis found that some notable exceptions are distorting that timeline. The median approval time for “rank and file” drugs is 8 days early, which lines up with the 7 days under Robert Califf, MD, and is actually slower than the 2 weeks ahead of the PDUFA that the FDA had under Margaret Hamburg, MD, in 2014.After reporting 5 deaths, a trial of a Parkinson’s disease drug stopped enrollment of new patients. Acorda Therapeutics said that 7 patients developed sepsis, and 4 of the fatal cases were tied to a condition in which white blood cells aren’t present to fight infections, reported The Wall Street Journal. The company is going to monitor blood-cell counts for patients in the phase 3 trial. The drug, tozadenant, is supposed to improve motor function in patients with Parkinson’s disease. Acorda acquired the drug when it bought a Finland-based company in 2016.Anthem Blue Cross is being fined for its poor response to consumer grievances. California’s Department of Managed Health Care has criticized the insurer for failing to resolve grievances in a timely manner and not following the law regarding consumer complaints, according to California Healthline. The state is fining the company $5 million, which is just the latest in fines the company has had to pay—since 2002, California has fined Anthem more than $6 million for violations related to consumer grievances.
Homelessness Compounds Hospital Stay Challenges: Study Reveals Prolonged Discharge Struggles
March 28th 2024In this investigation, outcomes of interest were morbidity rate and length of hospital stay or a traumatic injury among a homeless population, and whether age and/or injury severity had an influence on that relationship—with implications for improving the discharge process for these patients.
Read More
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
Risk for Second Primary Melanoma Increases After Primary Melanoma Diagnosis as Men Age
March 28th 2024A population-based cohort study out of Norway has found that older men have a higher risk of developing second primary invasive melanoma following an initial primary melanoma, suggesting the benefits of increased surveillance in these patients.
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Wearable Activity Tracker Data Enhance Patient Assessment in Lung Cancer
March 28th 2024This analysis included 119 patients with advanced lung cancer, who were evaluated on 3 facets of physical activity over 14 days of using the amuelink wearable device from Sony: metabolic equivalent tasks, distance walked, and steps taken.
Read More
CMS released a final rule to help patients obtain Children’s Health Insurance Program (CHIP) coverage and issued a proposed rule to update Medicare payment policies and rates for inpatient rehabilitation facilities; debate over if gift card incentives are acceptable in health care marketing.
Read More